Literature DB >> 33228367

From Lauren's diffuse gastric cancer to WHO's poorly cohesive carcinoma. Clinicopathological and prognostic characteristics.

Aingeru Sarriugarte Lasarte1, Eva García Alberdi2, Lorea Martínez Indart3, Oihane Gutiérrez Grijalba4, Irene Álvarez Abad4, Mikel Guerra Lerma4, Miguel Calle Baraja4, Alberto Colina Alonso5.   

Abstract

INTRODUCTION: since Lauren classified gastric cancer into intestinal-type adenocarcinoma and diffuse gastric carcinoma back in 1965, countless categorizations have been published that attempt to elucidate the clinicopathological and prognostic differences between histological subtypes.
OBJECTIVE: a retrospective study was performed of gastric cancer cases managed in a third-level site over ten years in order to compare subtypes between the most widely used classifications (Lauren and World Health Organization [WHO]).
METHODS: a comparative study of the most relevant clinicopathological characteristics and a multivariate survival analysis were performed.
RESULTS: significant differences exist between histological subtypes in terms of age, gender, location, extension, stage and treatment received. A univariate overall survival analysis revealed better survival rates for intestinal-type adenocarcinoma as compared to diffuse carcinoma (hazard ratio [HR]: 1.405 [1.024-1.927]) according to the Lauren's classification. Furthermore, there was a better prognosis of mucinous carcinoma (HR: 0.378 [0.164-0.868]), though failing to prove a poorer prognosis of poorly cohesive (HR: 1.242 [0.878-1.757]) and signet cell (HR: 1.354 [0.792-2.314]) carcinomas, according to the WHO classification. In the multivariate overall survival analysis, the following poor prognosis factors were identified: male gender, local infiltration (T), nodal invasion (N) and received adjuvant therapy.
CONCLUSION: although the various histological subtypes show significant clinicopathological differences, further studies are needed to compare them and clarify the prognostic relevance of each one.

Entities:  

Year:  2021        PMID: 33228367     DOI: 10.17235/reed.2020.7184/2020

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  4 in total

1.  PHLPP1 Overexpression was Associated With a Good Prognosis With Decreased AKT Activity in Gastric Cancer.

Authors:  Sun Yi Park; Sang-Ho Jeong; Eun-Jung Jung; Young-Tae Ju; Chi-Young Jeong; Ju-Yeon Kim; Taejin Park; Jiho Park; Tae-Han Kim; Miyeong Park; Jung Wook Yang; Young-Joon Lee
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma.

Authors:  Yue Wang; Tao Shi; Xuan Wang; Jinwei Hu; Lixia Yu; Qin Liu; Nandie Wu; Baorui Liu; Jia Wei
Journal:  J Transl Med       Date:  2021-09-22       Impact factor: 5.531

3.  Family history of malignant tumor is a predictor of gastric cancer prognosis: Incorporation into a nomogram.

Authors:  Fanke Wang; Liqiao Fan; Qun Zhao; Yu Liu; Zhidong Zhang; Dong Wang; Xuefeng Zhao; Yong Li; Bibo Tan
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

4.  Clinical Relevance of the Tumor Location-Modified Laurén Classification System for Gastric Cancer in a Western Population.

Authors:  J L Moore; A R Davies; A Santaolalla; M Van Hemelrijck; N Maisey; J Lagergren; J A Gossage; M Kelly; C R Baker
Journal:  Ann Surg Oncol       Date:  2022-01-18       Impact factor: 4.339

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.